Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer

Inclusion Criteria: * Pathologically confirmed squamous cell cancer of the head and neck * Eligible sites: oral cavity, oropharynx, hypopharynx, larynx. * Patients requiring postoperative IMRT. * KPS \> 70%. * Patient has signed specific protocol consent prior to registration. * Calcium test within normal limits. * No previous malignancy except for non-melanoma skin cancer or cancer not of head and neck and controlled for at least 5 years. * Labs completed with 30 days of registration (CBC \& platelet, Ca++, Alk phos, SGOT, Bili, albumin) CXR and CT simulation. * Liver CT if alk phos, SGOT, or bili elevated. * Bone scan if elevated alk phos Exclusion Criteria: * Metastatic disease. * Patient using Salagen or concurrent chemotherapy. * Previous XRT for head and neck tumors. * Active untreated infection.